AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02769637
Drug: PPI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI treatment or no PPI treatment
Trial: NCT04159142
Drug: Nab-paclitaxel + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；
Trial: NCT00461344
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01232543
Drug: Product 0405
RxNorm normalized name: Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product 0405 will be administered topically, twice daily for 28 days.
Trial: NCT03649841
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo ADT
Trial: NCT01529060
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
Trial: NCT01449513
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel vehicle of PEP005
Trial: NCT03952143
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03044938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
Trial: NCT02562365
Drug: Etoposide, Cyclophosphamide, Carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
Trial: NCT02865564
Drug: ampicillin and gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01926548
Drug: Gleevec film-coated tablet 2 x 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03060044
Drug: Seretide Diskus with charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01986920
Drug: A-101 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Concentration of A-101 applied to one of 4 Target Lesions
Trial: NCT01986920
Drug: A-101 32.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
Trial: NCT01986920
Drug: A-101 40%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Concentration A-101 applied to one of 4 Target Lesions
Trial: NCT01359566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
Trial: NCT00535951
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00182312
Drug: Caffeine citrate injection
RxNorm normalized name: Caffeine Citrate Injection
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
Trial: NCT03469583
Drug: EYP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EYP001 self administered capsules, morning, with non carbonated water
Trial: NCT01495858
Drug: Naproxen Sodium 440 mg (BAYH6689)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
Trial: NCT01495858
Drug: DPH 50 mg
RxNorm normalized name: DPH 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Trial: NCT00262964
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
Trial: NCT02552342
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04234672
Drug: [14C]TAK-831 IV Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]TAK-831 IV infusion.
Trial: NCT04234672
Drug: [14C]TAK-831 Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]TAK-831 oral suspension.
Trial: NCT00239811
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04429854
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
Trial: NCT00190814
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00599664
Drug: OMS201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMS201 irrigation solution during surgery
Trial: NCT02865356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical vehicle solution
Trial: NCT00581971
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
Trial: NCT04523818
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04523818
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01804777
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet.
Trial: NCT02651753
Drug: Lipitor + Lipidil supra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Drug: Lipitor + Lipidil supra
Trial: NCT03668860
Drug: Celestone Soluspan 6Mg/Ml Suspension for Injection
RxNorm normalized name: Celestone Soluspan 6mg/ml Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular. Total dose: 1 mL (6 mg)
Trial: NCT01510730
Drug: eradication treatment of Helicobacter pylori infection
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
Trial: NCT02549092
Drug: Levodopa-Carbidopa Intestinal Gel
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00501371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soft-gel capsule, Qd, 12 weeks
Trial: NCT03677622
Drug: Voluven to near maximal stroke volume of the heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
Trial: NCT02597101
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study drug
Trial: NCT02597101
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for AZD9668 to be added to background drugs
Trial: NCT01852435
Drug: R-CEOP-70
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01852435
Drug: R-CEOP-90
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02008565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
Trial: NCT00002654
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01190163
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00108914
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01210170
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo inhalation before albuterol.
Trial: NCT02745925
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01853553
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood pressure medication.
Trial: NCT03759522
Drug: DPA-714 PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPA-714 PET/MRI
Trial: NCT02155205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03151057
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03904303
Drug: A 06 ad
RxNorm normalized name: tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colonic cleansing before colonoscopy and CT colonografi
Trial: NCT00097773
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
Trial: NCT02003547
Drug: AMA0076
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02003547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01306630
Drug: tivozanib (AV-951) and capecitabine (Xeloda®)
RxNorm normalized name: capecitabine Oral Tablet [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
Trial: NCT01134848
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml/kg
Trial: NCT01134848
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml IM
Trial: NCT00968201
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one chewable placebo tablet, once daily at bedtime for 12 weeks
Trial: NCT00716534
Drug: Placebo for ABT-869
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator (12.5 mg or 7.5 mg)
Trial: NCT00323856
Drug: Alphanate SD/HT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived preparation of Factor VIII
Trial: NCT00362349
Drug: IgNextGen 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days
Trial: NCT00291057
Drug: MALG
RxNorm normalized name: Amalgam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minute application
Trial: NCT02879877
Drug: UCB7858
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02879877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00072566
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01138436
Drug: MEBO Wound Ointment (MEBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application once a day
Trial: NCT00389064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
Trial: NCT01895205
Drug: Red blood cell transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02478957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo administered via inhalation three times daily for 6 weeks
Trial: NCT02325037
Drug: GLPG1837 single ascending doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral suspension
Trial: NCT01421940
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
Trial: NCT02372630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo giving orally daily
Trial: NCT03882203
Drug: CLAGE-FluBu
RxNorm normalized name: INFLUENZA A VIRUS A/VIETNAM/1203/2004 (H5N1, CLADE 1) ANTIGEN (FORMALDEHYDE INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
Trial: NCT02325037
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral suspension matching placebo
Trial: NCT02325037
Drug: Placebo multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses, daily for 14 days, oral suspension, matching placebo
Trial: NCT05340010
Drug: Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
Trial: NCT01069926
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral tablet
Trial: NCT00191022
Drug: LY686017
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00191022
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03301285
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment of osteoporosis
Trial: NCT00119015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00416520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Trial: NCT02992938
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00633399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo.
Trial: NCT04132011
Drug: Extended Release Opioid Formulation, Shortened Intervals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
Trial: NCT04132011
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose pill manufactured to mimic extended release opioid formulation
Trial: NCT04280263
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
Trial: NCT04280263
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
Trial: NCT02932878
Drug: DSXS topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment
Trial: NCT00620022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Trial: NCT01710657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral Placebo tablets twice daily for 16 weeks.
Trial: NCT02187562
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02662712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
Trial: NCT02476799
Drug: IV-PCA containing Fentanyl and Ketorolac
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
Trial: NCT00270322
Drug: Marcaine 0.166% + Fentanyl 3.33 mcg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03958422
Drug: cardiomyopeptidin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
Trial: NCT00437658
Drug: Placebo to DMPA-SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for subcutaneous injection in a pre-filled syringe
Trial: NCT00233597
Drug: ferumoxytol or oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02068105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet
Trial: NCT03204266
Drug: Arginine recovery supplement
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
Trial: NCT03953950
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
Trial: NCT01916317
Drug: 0.5% lignocaine 60mM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00151047
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03824314
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
Trial: NCT01480752
Drug: Lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
Trial: NCT00804570
Drug: LY2196044
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Trial: NCT00804570
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, orally, 16 weeks
Trial: NCT00487136
Drug: warfarin plus ABT-335 plus rosuvastatin 5 mg
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
Trial: NCT00487136
Drug: warfarin plus ABT-335 plus rosuvastatin 20 mg
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
Trial: NCT01480752
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
Trial: NCT01166100
Drug: Fluoxetine Hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Trial: NCT02254174
Drug: Serevent® Diskus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254174
Drug: Spiriva®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01520909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with no active pharmaceutical ingredient
Trial: NCT02226185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: supplement of placebo two times per day for 2-3 years